Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning
Journal of Personalized Medicine · 23.10.2024 · 14 (11) · 1068
DOI: 10.3390/jpm14111068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 23.10.2024. Verfasst von Kaiyuan Gong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science & Artificial Intelligence, IMT Mines Ales, 30100 Ales, France. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Radioligandtherapy (RLT) with [177Lu]Lu-PSMA has been newly introduced as a routine treatment for metastatic castration-resistant prostate cancer (mCRPC). However, not all patients can tolerate the entire therapeutic sequence, and in some cases, the treatment may prove ineffective. In real-world conditions, the aim is to distinguish between patients who fully benefit from treatment (those who respond effectively and tolerate the entire therapeutic sequence) and those who do not respond or cannot tolerate the entire sequence. This study explores predictive factors to distinguish between fully beneficial RLT treatment patients (FBTP) and not fully beneficial RLT treatment patients (NFBTP). The objective was to enhance the understanding of predictive factors influencing RLT effectiveness and to highlight the significance of machine learning in optimizing patient selection for treatment planning.
Methods
Data from 25 mCRPC patients, categorized as FBTP (11) or NFBTP (14) to RLT, were analyzed. The dataset included clinical, imaging, and biological parameters. Data analysis techniques, including exploratory data analysis and feature engineering, were used to develop machine learning models for predicting patient outcomes.
Results
Imaging data analysis revealed statistically significant differences in the renal uptake intensity of Choline between the two groups. A discordance of FDG+ and PSMA− was identified as a potential indicator of NFBTP. The integration of biological data enhanced the model’s predictive capability, achieving an accuracy of 0.92, a sensitivity of 0.96, and a precision of 0.96. Adding blood parameters like neutrophils, leukocytes, and alkaline phosphatase greatly increased prediction accuracy.
Conclusions
This study emphasizes the significance of an integrated approach that merges imaging and biological data, thereby augmenting the predictive accuracy of patient outcomes in RLT with [177Lu]Lu-PSMA. In particular, including Choline PET among the imaging parameters provides unique insights into the predictive factors affecting RLT efficacy. This approach not only deepens the understanding of predictive factors but also underscores the utility of machine learning in refining the patient selection process for optimized treatment planning.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Computer Science & Artificial Intelligence, IMT Mines Ales, 30100 Ales, France.
- Service de Médecine Nucléaire, Centre Hospitalier Universitaire de Nîmes, Université de Montpellier, 34295 Nîmes, France.
- EuroMov Digital Health in Motion, Université de Montpellier, IMT Mines Ales, 30100 Ales, France.
- Faculty of Medicine, Université de Montpellier, Nimes Caremeau Campus, 34295 Nîmes, France.
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298 Montpellier, France.
- Service d'Oncologie Centre Hospitalier Universitaire de Nîmes, Université de Montpellier, 34295 Nîmes, France.
ORCID-Profile: Baptiste Magnier, Adel Mamou, Laurent Maimoun
Zitieren
APA
Gong, K., Magnier, B., L'hostis, S., Borrely, F., Le Bon, S., Houede, N., Mamou, A., Maimoun, L., Kotzki, P. O., & Boudousq, V. (2024). Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning. Journal of Personalized Medicine, 14(11), 1068. https://doi.org/10.3390/jpm14111068
Vancouver
Gong K, Magnier B, L'hostis S, Borrely F, Le Bon S, Houede N, et al. Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning. Journal of Personalized Medicine. 2024;14(11):1068. doi:10.3390/jpm14111068
BibTeX
@article{Gong2024,
author = {Gong, Kaiyuan and Magnier, Baptiste and L'hostis, Salomé and Borrely, Fanny and Le Bon, Sébastien and Houede, Nadine and Mamou, Adel and Maimoun, Laurent and Kotzki, Pierre Olivier and Boudousq, Vincent},
title = {Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning},
journal = {Journal of Personalized Medicine},
year = {2024},
volume = {14},
number = {11},
pages = {1068},
doi = {10.3390/jpm14111068}
}
EUVIMED